Company Filing History:
Years Active: 1991-2001
Title: Innovations in Viral Inactivation: The Contributions of Nicholas E. Geacintov
Introduction
Nicholas E. Geacintov, a notable inventor based in New York, NY, has made significant strides in the field of viral inactivation. With a total of four patents to his name, Geacintov's work primarily focuses on processes that enhance the safety of blood products through innovative photoreactive techniques. His inventions have implications for transfusion medicine, particularly in ensuring the safety and reliability of blood cell compositions.
Latest Patents
Geacintov's most recent patents center around processes for the photoreactive inactivation of viruses present in blood cell or coagulation factor-containing compositions. One of his key inventions describes a method for inactivating both extracellular lipid enveloped and intracellular human pathogenic viruses in blood cell compositions. This process involves using a virucidally effective amount of a photoreactive compound with a specific absorption maximum, along with light and oxygen or a quencher. Remarkably, this method retains over 80% integrity of the blood cells treated.
Another notable patent involves the photodynamic inactivation of viruses without substantial disruption to the cells. This entails the same effective combination of photoreactive compounds, light, and oxidizers, ensuring that the functionality of the cells is preserved while inactivating the virus. This innovation opens up new avenues for processing blood products for transfusion, ensuring safer options for patients in need.
Career Highlights
Nicholas E. Geacintov is currently affiliated with the New York Blood Center, Inc., where he continues to develop and refine his groundbreaking technologies in the field of transfusion safety. His innovative contributions underscore the importance of advancing techniques that safeguard public health, demonstrating a commitment to research and practical solutions in medicine.
Collaborations
Throughout his career, Geacintov has collaborated with esteemed colleagues, including Bernard Horowitz and Jay E. Valinsky. These partnerships highlight the collaborative nature of research and innovation, fostering a rich environment for the development of new ideas and techniques that push the boundaries of what is possible in viral inactivation and transfusion medicine.
Conclusion
Ultimately, Nicholas E. Geacintov's work represents a significant advancement in the field of medical technology, specifically in ensuring the safety of blood transfusions. His innovative approaches to viral inactivation not only enhance the quality of blood products but also exemplify the critical role that dedicated inventors play in improving healthcare outcomes. As research in this area continues to evolve, Geacintov's contributions will undoubtedly serve as a foundation for future innovations.